在心房动严重出血后,抗凝血的时间重新启动
Nour Al-Hussainy1, Kristian Kragholm2, Søren Lundbye-Christensen3
1Cardiology, Aalborg University Hospital, Aalborg, Denmark dr.radha@hotmail.com.
Heart (British Cardiac Society)
|July 16, 2025
概括
在心房 (AF) 患者出血后早期重新开始直接口服抗凝剂 (DOACs),可能会降低中风风险,但会增加出血. DOAC 单疗法提供了中风保护,但具有较高的出血风险,需要个性化治疗决策.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
- 临床研究 临床研究
背景情况:
- 在心房患者严重出血后,直接口服抗凝剂 (DOAC) 的管理具有挑战性.
- 关于平衡中风预防和再出血风险的证据有限.
研究的目的:
- 调查早期和晚期DOAC重新启动对AF患者中风和出血事件的影响.
- 评估不同抗血栓治疗方案的有效性.
主要方法:
- 全国范围的丹麦注册数据 (2012-2021) 的AF患者经历严重出血在DOACs.
- 早期 (<60天) 和晚期 (>60天) DOAC重新启动之间的结果比较.
- 采用多变量考克斯模型和时间变化的分析.
主要成果:
- 早期的DOAC重新启动 (n=5970) 显示了较低中风风险 (HR 0.89) 的趋势,但与迟重新启动 (n=4321) 相比,明显更高的复发性出血风险 (HR 1.21) .
- DOAC单疗与降低中风风险 (HR 0.78) 相关,但也增加了出血风险 (HR 1.26).
结论:
- 在AF患者出血后早期恢复DOAC可能会减少中风,但会增加再次出血的风险.
- DOAC单疗提供中风益处,但携带更高的出血风险,强调了个性化患者管理和进一步研究的必要性.
相关概念视频
Venous Thrombosis III: Interprofessional Care
25
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
25
Anticoagulant Drugs: Low-Molecular-Weight Heparins
917
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
917
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.3K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.3K
Clot Retraction and Fibrinolysis
6.9K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
6.9K
Venous Thrombosis IV: Nursing Management
25
Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
25
Acute Coronary Syndrome IV: Interprofessional Care
32
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
32


